Related Experiment Video
Updated: Jun 1, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
[Rationale and clinical evidence for the use of rituximab in glomerular diseases]
Laila-Yasmin Mani1, Bruno Vogt, Michel Burnier
1Service de néphrologie et consultation d'hypertension, Département de médecine, CHUV, 1011 Lausanne. laila-yasmin.mani@chuv.ch
Abstract:
Autoimmune glomerulopathies are an important cause of chronic kidney disease. Conventional treatments based on steroids, antiproliferative and cytotoxic agents are efficacious, but highly toxic. Because of their central role in the pathogenesis of autoimmunity, B cells have become an attractive therapeutic target. Rituximab is a monoclonal antibody directed against CD20 expressed on the surface of B cells, inducing profound depletion of B cells in the peripheral blood. In spite of encouraging results regarding the off-label use of Rituximab in membranous nephropathy, systemic lupus erythematosus and small vessel vasculitis, controlled, long-term data, and data with specific renal endpoints are currently lacking.
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Nephrotic Syndrome II : Assessment and Medical Management
Chronic Kidney Disease II: Clinical Manifestations
Rheumatic Heart Disease III: Medical Management
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
